CAI Caris Life Sciences, Inc.
Healthcare$15.52-0.19%ClosedMarket Cap: $4.39B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.40
P/S
4.84
EV/EBITDA
34.21
DCF Value
$-13.02
FCF Yield
2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
15.9%
Net Margin
3.7%
ROE
6.5%
ROA
2.9%
ROIC
14.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $216.2M | 65.4% | $5.3M | $-510.0K | $— | — |
| Q4 null | $292.9M | 75.4% | $88.4M | $82.0M | $— | — |
| FY null | $812.0M | 66.4% | $45.1M | $-538.0M | $— | — |
| Q3 null | $216.8M | 68.0% | $32.6M | $24.3M | $— | — |
| Q2 null | $181.4M | 62.7% | $18.0M | $-71.8M | $— | — |
| Q1 null | $120.9M | 47.2% | $-58.0M | $-102.6M | $— | — |
| FY null | $412.3M | 43.4% | $-257.1M | $-281.9M | $— | — |
| Q2 null | $100.0M | 37.5% | $67.0M | $-66.2M | $— | — |
| Q1 null | $80.7M | 32.4% | $-92.2M | $-111.0M | $— | — |
| FY null | $306.1M | 29.2% | $-319.6M | $-341.4M | $— | — |
| FY null | $258.5M | 31.0% | $-315.8M | $-320.8M | $— | — |
| Q3 null | $100.8M | 53.6% | $66.4M | $51.2M | $— | — |